Recombinant Phaseolus vulgaris phytohemagglutinin L-form expressed in the Bacillus brevis exerts in vitro and in vivo anti-tumor activity through potentiation of apoptosis and immunomodulation.
Researchers have successfully created a new form of Leukocyte phytohemagglutinin (PHA-L) through recombinant protein production. PHA-L, known for its antitumor and immunomodulatory effects, has potential as an antineoplastic agent in cancer treatment. However, previous acquisition methods have led to negative consequences such as toxicity and immunogenicity. The recombinant PHA-L protein demonstrated stronger antitumor effects and lower toxicity compared to natural PHA-L. This study provides a new strategy for developing drugs with immune regulation and direct antitumor activity.
- Wang P et al (2023).
- Int Immunopharmacol.
- PubMed:
- 37269742